Non-melanoma Skin Cancer Market size to grow at a CAGR of 5.76% from 2021 to 2026, Driven by the NMSC coverage and support - Technavio

NEW YORK, April 12, 2023 /PRNewswire/ -- The non-melanoma skin cancer market size is forecasted to increase by USD 180.97 million from 2021 to 2026, at a CAGR of 5.76%, according to the recent market study by Technavio. The growth of the market will be driven by the NMSC coverage and support, an increase in awareness about skin cancer, and initiatives by organizations. Technavio offers an up-to-date analysis of the current global market scenario and the overall market environment. View a Sample Report. 

Non-melanoma Skin Cancer Market - Vendor Analysis:

The global non-melanoma skin cancer market is a fragmented market, with a number of competitors. Vendors are expanding their product portfolios to sustain their market shares with many vendors capturing the market inorganically. Technavio has extensively analyzed 15 major vendors, including 3M Corp., Almirall SA, Amgen Inc., Bausch Health Companies Inc., Bristol Myers Squibb Co., Elekta AB, Eli Lilly and Co., F. Hoffmann La Roche Ltd., GlaxoSmithKline Plc, iCAD Inc., Merck and Co. Inc., Mylan N.V, Novartis AG, Pfizer Inc., Sensus Healthcare Inc., Sun Pharmaceutical Industries Ltd., Varian Medical Systems Inc., and Vidac Pharma.

Get a holistic overview of the market by industry experts to evaluate and develop growth strategies. Download the Sample

Vendor Offerings -

• 3M Corp. - The company offers non-melanoma skin cancer drugs, which include Aldara (imiquimod) cream to treat superficial basal cell carcinoma, a form of non-melanoma skin cancer.
• Almirall SA - The company offers non-melanoma skin cancer drugs, which include Sativex for the treatment of spasticity in multiple sclerosis. Actikerall has been approved for the treatment of hyperkeratotic actinic keratosis.
• Bausch Health Companies Inc. - The company offers non-melanoma skin cancer drugs, which include Aldara cream, which is used in actinic keratosis and superficial basal cell nonmelanoma skin cancer.
• For more insights on vendors and their offerings - Request a Sample Report!

Key Benefits for Industry Players & Stakeholders – 

• The report offers information on the criticality of vendor inputs, including R&D, CAPEX, and technology.
• It also provides detailed analyses of the market's competitive landscape and vendors' product offerings.
• The report also provides a qualitative and quantitative analysis of vendors to help clients understand the wider business environment as well as the strengths and weaknesses of key market players. Data is qualitatively analyzed to categorize vendors as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize vendors as dominant, leading, strong, tentative, and weak.

Expand operations in the future - To get requisite details, ask for a custom report.

Non-melanoma Skin Cancer Market - Market Segmentation:

This report extensively covers non-melanoma skin cancer market segmentation by type (BCC and SCC) and geography (North America, Europe, Asia, and Rest of World (ROW)).

• The market share growth by the BCC segment will be significant for the market growth during the forecast period. The segment accounts for approximately 80% of NMSC. The occurrence of BCC is estimated to have been rising by 2% a year in the US and 5% a year in Europe. In APAC, Australia has the highest number of patients diagnosed with BCC by the age of 70. There has been an increase in surgical treatments and an increase in awareness of BCC among the general population and physicians in the past few years. BCCs can lead to severe disfigurement of the body, though the mortality rate is low. Additionally, it has been observed that the occurrence of BCC is 11.4 times more common in HIV-infected individuals compared to the general population. 

Charts & data tables about market and segment sizes for forecast period (2022-2026) have been covered in this report. Download the Sample Report

Non-melanoma Skin Cancer Market - Market Dynamics:

Key Drivers:

• A major driver fueling the growth of the non-melanoma skin cancer market during the forecast period is the NMSC coverage and support.
• Diagnosis costs, treatment costs, repair charges, facility fees, pathology costs, and other peripheral costs are among the direct medical costs to treat NMSC. The treatment costs include destruction, excision, and Mohs surgery. The treatment costs are covered by most payers and Medicare. 
• Substantial efforts and multiple physician visits are required for most pharmacotherapy approaches when compared with surgery. Thus, pharmacotherapy approaches are less preferred by physicians.
• Drugs can be reimbursed based on evaluation and management codes. Documents regarding the type and severity of patient conditions and bills for reimbursement must be provided, and the choice of treatment is probably based on the disease type, severity, and patient demand because of differences in reimbursement for the two approaches, namely surgery and drugs. 
• Moreover, most drugs for NMSC are reimbursed by the manufacturing company in the form of coupons and patient assistance for low-income groups.

Major Trends:

• The increasing incidence of NMSC is a trend that is expected to have a positive impact on the market during the forecast period.
• NMSC is the most common malignancy associated with considerable morbidity and substantial cost, as well as comparatively small but significant mortality worldwide.
• There has been a significant increase in the number of NMSCs and affected individuals in the US, according to the national claims and survey databases.
• For instance, between 1992 and 2012, the incidence rate of skin cancer continued to rise, with a 100% increase among the Medicare fee-for-service population.
• Hence, such factors will drive the market growth during the forecast period.

Key Challenges:

• There are few drugs in the pipeline for NMSC, which is challenging market growth.
• The drug pipeline for NMSC has very few molecules due to the low amount of R&D in this area, with non-disease-modifying drugs being under evaluation.
• Most drugs are evaluated for palliative care or as adjuvant therapy, and the topical drugs used for NMSC are imiquimod (Aldara and ZYCLARA) and 5-fluorouracil (5-FU, Efudex, and Actikerall). 
• Various studies are conducted to test newer targeted drugs for the treatment of advanced SCC. 
• Cells from this type of cancer consist of the epidermal growth factor receptor (EGFR), and the drugs that target this protein, such as Cetuximab (ERIBUTEX), are being tested in clinical trials.
• Hence, the lack of a strong pipeline of NMSC drugs and the long approval time for drugs are expected to hamper the growth of the global NMSC market during the forecast period.

To get detailed insights about drivers, trends, and challenges, buy the report 

What are the key data covered in this non-melanoma skin cancer market report?

• CAGR of the market during the forecast period
• Detailed information on factors that will drive the growth of the non-melanoma skin cancer market between 2022 and 2026
• Precise estimation of the size of the non-melanoma skin cancer market and its contribution to the market in focus on the parent market
• Accurate predictions about upcoming trends and changes in consumer behavior
• Growth of the non-melanoma skin cancer market across North America, Europe, Asia, and Rest of World (ROW)
• A thorough analysis of the market's competitive landscape and detailed information about vendors
• Comprehensive analysis of factors that will challenge the growth of non-melanoma skin cancer market vendors

Gain instant access to 17,000+ market research reports. 
Technavio's SUBSCRIPTION platform

Related Reports:

• The colorectal cancer therapeutics market size is expected to increase by USD 2.45 billion from 2021 to 2026, and the market's growth momentum will accelerate at a CAGR of 5.43%. This report extensively covers market segmentation by type (targeted therapy, immunotherapy, and chemotherapy) and geography (North America, Europe, Asia, and Rest of World (ROW)). The increasing geriatric population is notably driving the colorectal cancer therapeutics market growth.
• The global breast cancer therapeutics market size is estimated to grow by USD 13.85 billion between 2021 to 2026 accelerating at a CAGR of 8.95%. This report extensively covers market segmentation by Product (targeted therapy, hormonal therapy, and chemotherapy) and Geography (North America, Europe, Asia, and Rest of World (ROW)). The rising number of patient support initiatives is the key factor driving the market growth.

Browse for Technavio's Health Care Market Reports

Key Topics Covered:

1 Executive Summary

• 1.1 Market overview
• Exhibit 01: Executive Summary – Chart on Market Overview
• Exhibit 02: Executive Summary – Data Table on Market Overview
• Exhibit 03: Executive Summary – Chart on Global Market Characteristics
• Exhibit 04: Executive Summary – Chart on Market by Geography
• Exhibit 05: Executive Summary – Chart on Market Segmentation by Type
• Exhibit 06: Executive Summary – Chart on Incremental Growth
• Exhibit 07: Executive Summary – Data Table on Incremental Growth
• Exhibit 08: Executive Summary – Chart on Vendor Market Positioning

2 Market Landscape

• 2.1 Market ecosystem
• Exhibit 09: Parent market
• Exhibit 10: Market Characteristics

3 Market Sizing

• 3.1 Market definition
• Exhibit 11: Offerings of vendors included in the market definition

• 3.2 Market segment analysis 
• Exhibit 12: Market segments

• 3.3 Market size 2021

• 3.4 Market outlook: Forecast for 2021-2026 
• Exhibit 13: Chart on Global - Market size and forecast 2021-2026 ($ million)
• Exhibit 14: Data Table on Global - Market size and forecast 2021-2026 ($ million)
• Exhibit 15: Chart on Global Market: Year-over-year growth 2021-2026 (%)
• Exhibit 16: Data Table on Global Market: Year-over-year growth 2021-2026 (%)

4 Five Forces Analysis

• 4.1 Five forces summary
• Exhibit 17: Five forces analysis - Comparison between2021 and 2026

• 4.2 Bargaining power of buyers 
• Exhibit 18: Chart on Bargaining power of buyers – Impact of key factors 2021 and 2026

• 4.3 Bargaining power of suppliers 
• Exhibit 19: Bargaining power of suppliers – Impact of key factors in 2021 and 2026

• 4.4 Threat of new entrants 
• Exhibit 20: Threat of new entrants – Impact of key factors in 2021 and 2026

• 4.5 Threat of substitutes 
• Exhibit 21: Threat of substitutes – Impact of key factors in 2021 and 2026

• 4.6 Threat of rivalry
• Exhibit 22: Threat of rivalry – Impact of key factors in 2021 and 2026

• 4.7 Market condition
• Exhibit 23: Chart on Market condition - Five forces 2021 and 2026

5 Market Segmentation by Type

• 5.1 Market segments
• Exhibit 24: Chart on Type - Market share 2021-2026 (%)
• Exhibit 25: Data Table on Type - Market share 2021-2026 (%)

• 5.2 Comparison by Type
• Exhibit 26: Chart on Comparison by Type
• Exhibit 27: Data Table on Comparison by Type

• 5.3 BCC - Market size and forecast 2021-2026 
• Exhibit 28: Chart on BCC - Market size and forecast 2021-2026 ($ million)
• Exhibit 29: Data Table on BCC - Market size and forecast 2021-2026 ($ million)
• Exhibit 30: Chart on BCC - Year-over-year growth 2021-2026 (%)
• Exhibit 31: Data Table on BCC - Year-over-year growth 2021-2026 (%)

• 5.4 SCC - Market size and forecast 2021-2026 
• Exhibit 32: Chart on SCC - Market size and forecast 2021-2026 ($ million)
• Exhibit 33: Data Table on SCC - Market size and forecast 2021-2026 ($ million)
• Exhibit 34: Chart on SCC - Year-over-year growth 2021-2026 (%)
• Exhibit 35: Data Table on SCC - Year-over-year growth 2021-2026 (%)

• 5.5 Market opportunity by Type 
• Exhibit 36: Market opportunity by Type ($ million)

6 Customer Landscape

• 6.1 Customer landscape overview 
• Exhibit 37: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria

7 Geographic Landscape

• 7.1 Geographic segmentation 
• Exhibit 38: Chart on Market share by geography 2021-2026 (%)
• Exhibit 39: Data Table on Market share by geography 2021-2026 (%)

• 7.2 Geographic comparison 
• Exhibit 40: Chart on Geographic comparison
• Exhibit 41: Data Table on Geographic comparison

• 7.3 North America - Market size and forecast 2021-2026 
• Exhibit 42: Chart on North America - Market size and forecast 2021-2026 ($ million)
• Exhibit 43: Data Table on North America - Market size and forecast 2021-2026 ($ million)
• Exhibit 44: Chart on North America - Year-over-year growth 2021-2026 (%)
• Exhibit 45: Data Table on North America - Year-over-year growth 2021-2026 (%)

• 7.4 Europe - Market size and forecast 2021-2026 
• Exhibit 46: Chart on Europe - Market size and forecast 2021-2026 ($ million)
• Exhibit 47: Data Table on Europe - Market size and forecast 2021-2026 ($ million)
• Exhibit 48: Chart on Europe - Year-over-year growth 2021-2026 (%)
• Exhibit 49: Data Table on Europe - Year-over-year growth 2021-2026 (%)

• 7.5 Asia - Market size and forecast 2021-2026 
• Exhibit 50: Chart on Asia - Market size and forecast 2021-2026 ($ million)
• Exhibit 51: Data Table on Asia - Market size and forecast 2021-2026 ($ million)
• Exhibit 52: Chart on Asia - Year-over-year growth 2021-2026 (%)
• Exhibit 53: Data Table on Asia - Year-over-year growth 2021-2026 (%)

• 7.6 Rest of World (ROW) - Market size and forecast 2021-2026 
• Exhibit 54: Chart on Rest of World (ROW) - Market size and forecast 2021-2026 ($ million)
• Exhibit 55: Data Table on Rest of World (ROW) - Market size and forecast 2021-2026 ($ million)
• Exhibit 56: Chart on Rest of World (ROW) - Year-over-year growth 2021-2026 (%)
• Exhibit 57: Data Table on Rest of World (ROW) - Year-over-year growth 2021-2026 (%)

• 7.7 US - Market size and forecast 2021-2026 
• Exhibit 58: Chart on US - Market size and forecast 2021-2026 ($ million)
• Exhibit 59: Data Table on US - Market size and forecast 2021-2026 ($ million)
• Exhibit 60: Chart on US - Year-over-year growth 2021-2026 (%)
• Exhibit 61: Data Table on US - Year-over-year growth 2021-2026 (%)

• 7.8 Canada - Market size and forecast 2021-2026 
• Exhibit 62: Chart on Canada - Market size and forecast 2021-2026 ($ million)
• Exhibit 63: Data Table on Canada - Market size and forecast 2021-2026 ($ million)
• Exhibit 64: Chart on Canada - Year-over-year growth 2021-2026 (%)
• Exhibit 65: Data Table on Canada - Year-over-year growth 2021-2026 (%)

• 7.9 UK - Market size and forecast 2021-2026 
• Exhibit 66: Chart on UK - Market size and forecast 2021-2026 ($ million)
• Exhibit 67: Data Table on UK - Market size and forecast 2021-2026 ($ million)
• Exhibit 68: Chart on UK - Year-over-year growth 2021-2026 (%)
• Exhibit 69: Data Table on UK - Year-over-year growth 2021-2026 (%)

• 7.10 Germany - Market size and forecast 2021-2026 
• Exhibit 70: Chart on Germany - Market size and forecast 2021-2026 ($ million)
• Exhibit 71: Data Table on Germany - Market size and forecast 2021-2026 ($ million)
• Exhibit 72: Chart on Germany - Year-over-year growth 2021-2026 (%)
• Exhibit 73: Data Table on Germany - Year-over-year growth 2021-2026 (%)

• 7.11 Japan - Market size and forecast 2021-2026 
• Exhibit 74: Chart on Japan - Market size and forecast 2021-2026 ($ million)
• Exhibit 75: Data Table on Japan - Market size and forecast 2021-2026 ($ million)
• Exhibit 76: Chart on Japan - Year-over-year growth 2021-2026 (%)
• Exhibit 77: Data Table on Japan - Year-over-year growth 2021-2026 (%)

• 7.12 China - Market size and forecast 2021-2026 
• Exhibit 78: Chart on China - Market size and forecast 2021-2026 ($ million)
• Exhibit 79: Data Table on China - Market size and forecast 2021-2026 ($ million)
• Exhibit 80: Chart on China - Year-over-year growth 2021-2026 (%)
• Exhibit 81: Data Table on China - Year-over-year growth 2021-2026 (%)

• 7.13 Market opportunity by geography 
• Exhibit 82: Market opportunity by geography ($ million)

8 Drivers, Challenges, and Trends

• 8.1 Market drivers

• 8.2 Market challenges

• 8.3 Impact of drivers and challenges 
• Exhibit 83: Impact of drivers and challenges in 2021 and 2026

• 8.4 Market trends

9 Vendor Landscape

• 9.1 Overview

• 9.2 Vendor landscape
• Exhibit 84: Overview on Criticality of inputs and Factors of differentiation

• 9.3 Landscape disruption
• Exhibit 85: Overview on factors of disruption

• 9.4 Industry risks
• Exhibit 86: Impact of key risks on business

10 Vendor Analysis

• 10.1 Vendors covered
• Exhibit 87: Vendors covered

• 10.2 Market positioning of vendors 
• Exhibit 88: Matrix on vendor position and classification

• 10.3 3M Corp.
• Exhibit 89: 3M Corp. - Overview
• Exhibit 90: 3M Corp. - Business segments
• Exhibit 91: 3M Corp. - Key news
• Exhibit 92: 3M Corp. - Key offerings
• Exhibit 93: 3M Corp. - Segment focus

• 10.4 Almirall SA
• Exhibit 94: Almirall SA - Overview
• Exhibit 95: Almirall SA - Product / Service
• Exhibit 96: Almirall SA - Key news
• Exhibit 97: Almirall SA - Key offerings

• 10.5 Bausch Health Companies Inc. 
• Exhibit 98: Bausch Health Companies Inc. - Overview
• Exhibit 99: Bausch Health Companies Inc. - Business segments
• Exhibit 100: Bausch Health Companies Inc. - Key news
• Exhibit 101: Bausch Health Companies Inc. - Key offerings
• Exhibit 102: Bausch Health Companies Inc. - Segment focus

• 10.6 Bristol Myers Squibb Co. 
• Exhibit 103: Bristol Myers Squibb Co. - Overview
• Exhibit 104: Bristol Myers Squibb Co. - Product / Service
• Exhibit 105: Bristol Myers Squibb Co. - Key offerings

• 10.7 Elekta AB
• Exhibit 106: Elekta AB - Overview
• Exhibit 107: Elekta AB - Business segments
• Exhibit 108: Elekta AB - Key news
• Exhibit 109: Elekta AB - Key offerings
• Exhibit 110: Elekta AB - Segment focus

• 10.8 F. Hoffmann La Roche Ltd. 
• Exhibit 111: F. Hoffmann La Roche Ltd. - Overview
• Exhibit 112: F. Hoffmann La Roche Ltd. - Business segments
• Exhibit 113: F. Hoffmann La Roche Ltd. - Key news
• Exhibit 114: F. Hoffmann La Roche Ltd. - Key offerings
• Exhibit 115: F. Hoffmann La Roche Ltd. - Segment focus

• 10.9 Mylan N.V
• Exhibit 116: Mylan N.V - Overview
• Exhibit 117: Mylan N.V - Product / Service
• Exhibit 118: Mylan N.V - Key offerings

• 10.10 Sun Pharmaceutical Industries Ltd. 
• Exhibit 119: Sun Pharmaceutical Industries Ltd. - Overview
• Exhibit 120: Sun Pharmaceutical Industries Ltd. - Product / Service
• Exhibit 121: Sun Pharmaceutical Industries Ltd. - Key offerings

• 10.11 Varian Medical Systems Inc. 
• Exhibit 122: Varian Medical Systems Inc. - Overview
• Exhibit 123: Varian Medical Systems Inc. - Business segments
• Exhibit 124: Varian Medical Systems Inc. - Key offerings
• Exhibit 125: Varian Medical Systems Inc. - Segment focus

• 10.12 Vidac Pharma
• Exhibit 126: Vidac Pharma - Overview
• Exhibit 127: Vidac Pharma - Product / Service
• Exhibit 128: Vidac Pharma - Key offerings

11 Appendix

• 11.1 Scope of the report

• 11.2 Inclusions and exclusions checklist 
• Exhibit 129: Inclusions checklist
• Exhibit 130: Exclusions checklist

• 11.3 Currency conversion rates for US$ 
• Exhibit 131: Currency conversion rates for US$

• 11.4 Research methodology
• Exhibit 132: Research methodology
• Exhibit 133: Validation techniques employed for market sizing
• Exhibit 134: Information sources

• 11.5 List of abbreviations 
• Exhibit 135: List of abbreviations

About Us

Technavio is a leading global technology research and advisory company. Their research and analysis focus on emerging market trends and provide actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions. With over 500 specialized analysts, Technavio's report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio's comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.

Contact
Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: [email protected]
Website: www.technavio.com/

SOURCE Technavio